Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
April 01, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
January 03, 2019 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
June 26, 2018 08:00 ET
|
aTyr Pharma, Inc.
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr...
Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
April 11, 2018 08:15 ET
|
Treos Bio Corp.
SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
Sunset Island Group Announces Update on Expansion and Retro Fit of Greenhouse
February 07, 2018 10:16 ET
|
Sunset Island Group, Inc.
SALINAS, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- SUNSET ISLAND GROUP, INC. (OTCQB:SIGO) is pleased to provide an update to its shareholders regarding the Retro Fit and Expansion...
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
January 05, 2017 09:05 ET
|
Ocera Therapeutics, Inc.
Data Support Feasibility of Oral OCR-002 as Maintenance Therapy for Patients with Hepatic Encephalopathy Company Plans to Initiate Phase 2a in H1 2017 with New Optimized Tablet Formulation PALO...
Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
September 19, 2016 09:05 ET
|
Ocera Therapeutics, Inc.
--Phase 2b STOP-HE Enrollment Surpasses 205 Patients; On Track to Complete in Q4 2016-- PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics,...
ContraFect Announces Fourth Quarter and Full Year 2015 Results
March 15, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 15, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
November 16, 2015 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...